(NASDAQ: EWTX) Edgewise Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.57%.
Edgewise Therapeutics's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast EWTX's revenue for 2026 to be $1,205,770,552, with the lowest EWTX revenue forecast at $1,205,770,552, and the highest EWTX revenue forecast at $1,205,770,552. On average, 2 Wall Street analysts forecast EWTX's revenue for 2027 to be $5,497,996,409, with the lowest EWTX revenue forecast at $4,395,985,586, and the highest EWTX revenue forecast at $6,600,007,232.
In 2028, EWTX is forecast to generate $26,768,740,870 in revenue, with the lowest revenue forecast at $17,451,942,200 and the highest revenue forecast at $36,085,539,541.